SynthesisDiabetes, obesity & metabolism2022
Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: A systematic literature review.
Synthesis in Diabetes, obesity & metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Adherence to newer second-line oral antidiabetic drugs among people with type 2 diabetes-A systematic review.Pharmacology research & perspectives · 2024Pooled it
- Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: A systematic literature review.Diabetes, obesity & metabolism · 2022Pooled it
- Intense simplified strategy for newly diagnosed type 2 diabetes in patients with severe hyperglycaemia: multicentre, open label, randomised trial.BMJ (Clinical research ed.) · 2024Trial
- Effect of the initial combination approach vs initial monotherapy approach on 1-year trajectories of adherence in drug-naive patients with type 2 diabetes.Journal of managed care & specialty pharmacy · 2026Article
- Device-measured baseline physical activity is associated with 24-h CGM glycemic responses and 12-week time-in-range after mixed exercise training in type 2 diabetes: a randomised crossover trial.BMC sports science, medicine & rehabilitation · 2026Article
- The cost-effectiveness of value-based insurance design initiatives in managing cardiometabolic diseases: a systematic review.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Diabetes, hyperglycemia, and brain MRI biomarkers: results from SOL-INCA MRI study.Nutrition & diabetes · 2026Article
- Type 2 diabetes mellitus.Nature reviews. Disease primers · 2026Review
- Article
- Disease control and its correlates among hypertensive, diabetic, and asthmatic patients enrolled in secondary-level Integrated Chronic Care Clinics in Neno District, rural Malawi.PLOS global public health · 2026Article
- Perceived Barriers and Supports to Medication Adherence in Type 2 Diabetes: A Qualitative Study of Patients with and without a Zero-Dollar Copay Health Plan Benefit.Patient preference and adherence · 2026Article
- Medication adherence trajectories and association with risk factors and clinical outcomes in type 2 diabetes treatment.PloS one · 2026Article
- Development and Validation of a Machine Learning Model for Predicting Medication Adherence Among Home-Dwelling Elderly Patients: A Retrospective Cross-Sectional Study.Patient preference and adherence · 2026Article
- Effect of Adherence to Oral Semaglutide on Glycemic Control in People With Type 2 Diabetes Treated With Metformin: Protocol for an Open-Label Clinical Trial.JMIR research protocols · 2025Article
- Article
- The Relationship Between Spiritual Well-Being and Treatment Compliance in Adult Patients with Type 2 Diabetes in Northwestern Türkiye.Journal of religion and health · 2025Article
- Adherence to physician visits for diabetes care and cardiovascular disease risk: A retrospective cohort study using an administrative claims database.Diabetes, obesity & metabolism · 2025Article
- Clinically meaningful improvements in treatment satisfaction in insulin-naïve people with type 2 diabetes post initiation of insulin glargine 300 U/mL: A post hoc analysis of real-world ATOS study.Diabetes, obesity & metabolism · 2025Article
- Healthcare Resource Utilization and Costs in Individuals Who Discontinue Liraglutide and Who Switch from Liraglutide to Once-Weekly Injectable Semaglutide.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Article
- Association between Self-Care Behaviors and Inadequate Glycemic Control in ELSA-Brasil Participants with Type 2 Diabetes.Arquivos brasileiros de cardiologia · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We designed a systematic literature review to identify available evidence on adherence to and persistence with antidiabetic medication in people with type 2 diabetes (T2D). Electronic screening and congress searches identified real-world noninterventional studies (published between 2010 and October 2020) reporting estimates of adherence to and persistence with antidiabetic medication in adults with T2D, and associations with glycaemic control, microvascular and/or macrovascular complications, hospitalizations and healthcare costs. Ninety-two relevant studies were identified, the majority of which were retrospective and reported US data. The proportions of patients considered adherent (median [range] 51.2% [9.4%-84.3%]) or persistent (median [range] 47.7% [16.9%-94.0%]) varied widely across studies. Multiple studies reported an association between greater adherence/persistence and greater reductions in glycated haemoglobin levels. Better adherence/persistence was associated with fewer microvascular and/or macrovascular outcomes, although there was little consistency across studies in terms of which outcomes were improved. More adherent and more persistent patients were typically less likely to be hospitalized or to have emergency department visits/admissions and spent fewer days in hospital annually than less adherent/persistent patients. Greater adherence and persistence were generally associated with lower hospitalization costs, higher pharmacy costs and lower or budget-neutral total healthcare costs compared with lower adherence/persistence. In conclusion, better adherence and persistence in people with T2D is associated with lower rates of microvascular and/or macrovascular outcomes and inpatient hospitalization, and lower or budget-neutral total healthcare expenditure. Education and treatment strategies to address suboptimal adherence and persistence are needed to improve clinical and economic outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.